BPC-157

BPC-157 is a synthetic 15-amino-acid peptide corresponding to a partial sequence of a protein (BPC) isolated from human gastric juice. In preclinical models its effects are attributed largely to modulation of the nitric oxide (NO) system — interacting with the L-arginine–NO pathway and NO synthase activity — and to promotion of angiogenesis through upregulation of VEGFR2 and downstream activation of the VEGFR2–Akt–eNOS and FAK–paxillin pathways, which drive endothelial-cell migration and tube formation. It has also been reported to influence growth-factor signalling and the gut–brain axis. Nearly all of this mechanistic work comes from rodent and in-vitro studies, and no validated human molecular target has been established.

The BPC-157 literature is almost entirely preclinical: hundreds of rodent and in-vitro studies — the large majority from a single research group (Sikiric and colleagues) — report accelerated healing of tendon, muscle, ligament, bone, gut and other tissues. Independent replication is limited, and as of 2026 there are no completed, peer-reviewed controlled human efficacy trials. BPC-157 is not approved as a drug by the FDA, EMA or any comparable regulator; in 2023 the US FDA flagged it among substances that raise significant safety concerns for compounding. Any human use is unstudied.

Educational overview only — no dosing instructions in the public hub.

Human safety has not been established in controlled trials: there are no robust data on long-term toxicity, immunogenicity or drug interactions in people. Because BPC-157 is pro-angiogenic, there is a theoretical concern about stimulating unwanted vascular growth (for example in an undiagnosed tumour), though this remains unproven in humans. In practice the dominant, concrete risk is product quality — gray-market 'research' vials vary in purity, may be underfilled or contain unverified salt forms, endotoxin or other impurities, and are used without any medical supervision.

BPC-157 sold outside pharmaceutical channels is unregulated material of unverified composition. A third-party Certificate of Analysis covering identity, purity (HPLC), quantification (to detect underfill) and mass spectrometry is the minimum verification, and even then sterility, endotoxin and stability are usually unknown. The content here describes what preclinical research reports, not a quality-assured medicine.

Research-use-only in most jurisdictions and not approved for human use by the FDA, EMA or comparable agencies. In 2023 the US FDA placed BPC-157 in a category of substances presenting significant safety risks for pharmacy compounding. It is not a licensed medicine and is not authorised as a dietary supplement or food ingredient.